代谢相关脂肪性肝病生活方式干预治疗进展  

Progress of lifestyle interventions for metabolic dysfunction-associated fatty liver disease

作　　者：纪童童 李鑫飞 于岩岩[1] 徐小元[1] 徐京杭[1] JI Tongtong;LI Xinfei;YU Yanyan;XU Xiaoyuan;XU Jinghang(Department of Infectious Diseases,Peking University First Hospital,Beijing 100034,China)

机构地区：[1]北京大学第一医院感染疾病科,北京100034

出　　处：《临床肝胆病杂志》2023年第8期1789-1796,共8页Journal of Clinical Hepatology

摘　　要：代谢相关脂肪性肝病(MAFLD)全球患病率高达25%~30%,MAFLD与肝硬化、肝细胞癌、肝外恶性肿瘤、糖尿病、心血管疾病的发病率和死亡率密切相关,带来了巨大的疾病负担。生活方式的改变,包括饮食和体育锻炼来实现减重,仍是现阶段MAFLD的一线治疗措施。本文拟综述生活方式干预治疗MAFLD的进展,旨在为MAFLD的治疗提供借鉴。The global prevalence of metabolic dysfunction-associated fatty liver disease(MAFLD)is as high as 25%-30%.MAFLD is closely associated with the morbidity and mortality of liver cirrhosis,hepatocellular carcinoma,extrahepatic malignancies,diabetes mellitus,and cardiovascular diseases,resulting in substantial burden of diseases.Lifestyle interventions using diet and exercise to achieve weight loss remains a first-line therapy in patients with MAFLD.This article reviews the progress of lifestyle interventions for MAFLD to provide a reference for the treatment of this disease.

关 键 词：代谢相关脂肪性肝病 非酒精性脂肪性肝病 治疗学 

分 类 号：R575.5[医药卫生—消化系统]